The local pharmaceutical company Globe Biotech Limited has been given approval to begin human trials of Bangavax, a single-dose Covid-19 vaccine.
Bangladesh Medical Research Council (BMRC) gave the approval in principle, said a letter signed by its director Prof. Dr. Ruhul Amin on Tuesday (Nov 23).
Earlier, Globe Biotech Limited completed trials on 56 monkeys over a period of three months.
According to the vaccine developers, Bangavax does not have any side effects. They obtained a 95% success rate conducting trials on monkeys. The success rate will only vary by about 2%, in human trials, they hoped.
In July last year, Globe Biotech announced that it was developing a Covid-19 vaccine.
On December 28, 2020, the DGDA gave permission to the pharmaceutical company to manufacture its Covid-19 vaccine for clinical trials.
Globe Biotech approached the DGDA on January 15 this year, seeking permission for clinical trials.
BDST: 1754 HRS, NOV 23, 2021